Cargando…

596 Application of Intravenous Immunoglobulin for Treatment of Chronic Autoimmune Urticaria

BACKGROUND: To develop a patogenetically justified method for treatment of the autoimmune form of chronic urticaria. METHODS: 14 patients with autoimmune urticaria (18–60 y-o., time since disease onset ranging from 6 weeks to 5 years), having positive autoserum test results (7 mm or more in 11 patie...

Descripción completa

Detalles Bibliográficos
Autor principal: Alyoshkin, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization Journal 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512593/
http://dx.doi.org/10.1097/01.WOX.0000411711.09881.b5
_version_ 1782251756222152704
author Alyoshkin, Vladimir
author_facet Alyoshkin, Vladimir
author_sort Alyoshkin, Vladimir
collection PubMed
description BACKGROUND: To develop a patogenetically justified method for treatment of the autoimmune form of chronic urticaria. METHODS: 14 patients with autoimmune urticaria (18–60 y-o., time since disease onset ranging from 6 weeks to 5 years), having positive autoserum test results (7 mm or more in 11 patients, 4.5–6.5 mm in 3 patients) were treated with intravenous immunoglobulin for 4 days (50 mL of 5% immunoglobulin solution per day). Intravenous immunoglobulin of a fourth generation, containing 99.1 to 99.2% monomeric IgG, was applied. RESULTS: The treatment resulted in the rashes regressing in 13 (93%) patients after 3 to 4 days of treatment. All of the patients showed reduced autoserum test results (one of them was absolutely negative) 6 months after the end of treatment. Our investigations have shown a complete absence of clinical manifestations of urticaria within 1 year. CONCLUSIONS: Intravenous immunoglobulin, containing only monomeric IgG, has proven highly efficient in treatment of chronic autoimmune urticaria. The above-mentioned reduced autoserum test results suggest fourth-generation intravenous immunoglobulin's contribution to the pathogenesis of the disease.
format Online
Article
Text
id pubmed-3512593
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher World Allergy Organization Journal
record_format MEDLINE/PubMed
spelling pubmed-35125932012-12-21 596 Application of Intravenous Immunoglobulin for Treatment of Chronic Autoimmune Urticaria Alyoshkin, Vladimir World Allergy Organ J Abstracts of the XXII World Allergy Congress BACKGROUND: To develop a patogenetically justified method for treatment of the autoimmune form of chronic urticaria. METHODS: 14 patients with autoimmune urticaria (18–60 y-o., time since disease onset ranging from 6 weeks to 5 years), having positive autoserum test results (7 mm or more in 11 patients, 4.5–6.5 mm in 3 patients) were treated with intravenous immunoglobulin for 4 days (50 mL of 5% immunoglobulin solution per day). Intravenous immunoglobulin of a fourth generation, containing 99.1 to 99.2% monomeric IgG, was applied. RESULTS: The treatment resulted in the rashes regressing in 13 (93%) patients after 3 to 4 days of treatment. All of the patients showed reduced autoserum test results (one of them was absolutely negative) 6 months after the end of treatment. Our investigations have shown a complete absence of clinical manifestations of urticaria within 1 year. CONCLUSIONS: Intravenous immunoglobulin, containing only monomeric IgG, has proven highly efficient in treatment of chronic autoimmune urticaria. The above-mentioned reduced autoserum test results suggest fourth-generation intravenous immunoglobulin's contribution to the pathogenesis of the disease. World Allergy Organization Journal 2012-02-17 /pmc/articles/PMC3512593/ http://dx.doi.org/10.1097/01.WOX.0000411711.09881.b5 Text en Copyright © 2012 by World Allergy Organization
spellingShingle Abstracts of the XXII World Allergy Congress
Alyoshkin, Vladimir
596 Application of Intravenous Immunoglobulin for Treatment of Chronic Autoimmune Urticaria
title 596 Application of Intravenous Immunoglobulin for Treatment of Chronic Autoimmune Urticaria
title_full 596 Application of Intravenous Immunoglobulin for Treatment of Chronic Autoimmune Urticaria
title_fullStr 596 Application of Intravenous Immunoglobulin for Treatment of Chronic Autoimmune Urticaria
title_full_unstemmed 596 Application of Intravenous Immunoglobulin for Treatment of Chronic Autoimmune Urticaria
title_short 596 Application of Intravenous Immunoglobulin for Treatment of Chronic Autoimmune Urticaria
title_sort 596 application of intravenous immunoglobulin for treatment of chronic autoimmune urticaria
topic Abstracts of the XXII World Allergy Congress
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512593/
http://dx.doi.org/10.1097/01.WOX.0000411711.09881.b5
work_keys_str_mv AT alyoshkinvladimir 596applicationofintravenousimmunoglobulinfortreatmentofchronicautoimmuneurticaria